A cinetobacter baumannii has emerged as one of the most highly antimicrobial-resistant pathogens causing hospital-acquired infections in the United States and throughout the world, particularly in critically ill patients in intensive care units, those requiring mechanical ventilation, and patients with wound or burn injuries (1, 2) . A. baumannii has an extraordinary ability to develop resistance to even the most potent antimicrobial agents, and as a result, multidrug resistance (MDR) and extensive drug resistance (XDR), the latter defined as nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories (3) , are commonplace. Of note, the rate of carbapenem resistance has dramatically increased in the last decade, exceeding 40% by 2009 in the United States (4) (5) (6) . Infection due to XDR A. baumannii strains is typically treated with colistin, alone or in combination with other agents (1, 7) . Colistin (COL) is a cationic, amphiphilic antimicrobial peptide that interacts with the lipid A moiety of lipopolysaccharide (LPS) and causes disorganization of the bacterial membrane, leading to cell death (8) . Most A. baumannii strains are susceptible to colistin. However, colistin-resistant A. baumannii strains are emerging as a result of increased use of this agent. In fact, 5.3% of A. baumannii isolates identified in U.S. hospitals in 2010 were reported to be resistant to colistin (5) . Unfortunately, patients infected by colistin-resistant XDR strains of A. baumannii frequently succumb to the infection, as there are no effective treatment options. There are few data available to guide clinicians how to manage patients affected by colistin-resistant A. baumannii. To address this paucity of treatment options, agents whose activity is primarily against Gram-positive organisms have been tested, yielding some promising data against laboratory-adapted colistinresistant strains (9) . In addition, vancomycin has been shown to have activity against colistin-susceptible, XDR clinical strains in combination with colistin (10, 11) . The present study was conducted to investigate the activity of vancomycin-containing antimicrobial combinations against colistin-resistant XDR clinical strains of A. baumannii using time-kill assays and the Galleria mellonella infection model.
MATERIALS AND METHODS
Bacterial strains. Three unique colistin-resistant clinical strains of A. baumannii strains, all isolated at the University of Pittsburgh Medical Center, were used. A. baumannii JA637 was isolated from a lung transplant patient who was admitted in 2006. The clinical course of this patient has been described elsewhere (12) . A. baumannii JA566 was isolated from the sputum of a kidney transplant patient who had ventilator-associated pneumonia in 2009. A. baumannii JA942 was isolated from a bronchoalveolar lavage specimen of a liver transplant patient who also had ventilatorassociated pneumonia. All three patients had received therapy with colistin prior to the recovery of these strains for treatment of infection due to colistin-susceptible A. baumannii strains. MICs of doripenem (DOR) and vancomycin (VAN) were obtained with the Etest (bioMérieux, Hazelwood, MO). MICs of colistin were obtained by the standard agar dilution method (13) . All three strains produced the OXA-23 carbapenemase and belonged to sequence type 208 (ST 208), which is part of the global epidemic clonal complex 92 (CC 92) and Worldwide Clone 2 (14) .
Isolation and analysis of lipid A. Lipid A was isolated using a rapid extraction method described by El Hamidi et al. (15) . In brief, dried cells were resuspended in 100 l of endotoxin-free water and a 5:3 (vol/vol) mixture of isobutyric acid and 1 M ammonium hydroxide. The suspension was incubated for 1 h at 100°C. After incubation and a cooling step, the reaction mixture was centrifuged at 2,000 rpm for 15 min. The supernatant was transferred to a new tube, diluted with an equal volume of water, and lyophilized overnight. The dry material was then washed twice with 400 l of methanol. Insoluble lipid A was extracted in a (3:1.5:0.25 [vol/vol/vol]) mixture of chloroform, methanol, and water. For analysis, this extract was spotted onto a matrix-assisted laser desorption ionization-time of flight (MALDI) plate followed by norharmane matrix and air dried. The samples were analyzed on a Bruker AutoFlex Speed (Bruker Daltonics, Billerica, MA) mass spectrometer in the negative-ion mode, after calibration using Agilent tuning mix (Agilent Technologies, Santa Clara, CA).
Sequencing of genetic loci associated with colistin resistance. The genetic loci implicated in resistance to colistin in A. baumannii were amplified by PCR and sequenced as described previously. These included the pmrCAB operon encoding a two-component signal transduction system and lipid A phosphoethanolamine transferase and the lpxA, lpxC, and lpxD genes responsible for lipid A biosynthesis (16, 17) . For comparison, the loci were sequenced for the previous colistin-susceptible A. baumannii strains from the same patients.
Synergy studies. Synergy between two of the three agents of interest (colistin [COL], doripenem [DOR], and vancomycin [VAN]
) was assessed for a range of concentrations (between 0 and 64 g/ml) using the checkerboard method. In brief, wells with Mueller-Hinton (MH) broth containing doubling dilutions of each agent were inoculated with each strain in 96-well microtiter plates, as described previously (18) . The plates were incubated at 37°C overnight and visually inspected for turbidity to determine growth. Fractional inhibitory concentration indices (FICI) were calculated, and synergy was defined as an FICI of Յ0.5 (10).
Time-kill assays. Time-kill assays were conducted for each strain using the three agents alone and in all possible combinations according to a previously described methodology (18) . The final concentrations used were 2 g/ml for colistin, 8 g/ml for doripenem (18) , and 20 g/ml for vancomycin (10) . The concentration of colistin (2 g/ml) was selected as one that was achievable as the steady-state plasma concentration when pharmacokinetically optimized dosing is used (19) . MH broth was inoculated with 10 6 CFU/ml of the strain and incubated with shaking at 37°C. Colony counts were obtained at 4, 8, and 24 h to determine the viable CFU/ml. Bactericidal activity was defined as a Ն3-log-CFU/ml decrease in 4 or 8 h. Bacteriostatic activity was defined as a Ͻ3-log-CFU/ml decrease in 4 or 8 h.
G. mellonella assays. The G. mellonella infection model for A. baumannii was adapted from that proposed by Peleg et al. (20) . G. mellonella larvae were purchased from Grubco (Fairfield, OH), kept at room temperature, and used within 7 days from delivery. First, the lethal inoculum of the three A. baumannii strains was obtained by injection of 10 larvae with a range of inocula (10 2 to 10 6 CFU). The bacterial suspension was prepared in 10 mM MgSO 4 solution, and 5 l was injected into the hemocoels through the last left proleg using a 50-l syringe (SGE, Austin, TX). The larvae were incubated in petri dishes at 37°C and observed daily for 4 days. They were considered dead if they did not respond to touch. The mortalities at 3 days were 100% at 10 6 CFU and between 50 and 70% at 10 5 CFU. Based on these data, 5 ϫ 10 5 CFU was selected as the inoculum for the subsequent treatment experiments. For these experiments, 12 larvae were infected with 5 ϫ 10 5 CFU of each strain as described above. Then, the antimicrobial agents were injected in a 5-l solution, either alone or in combinations, through the last right proleg 30 Ϯ 5 min after infection. The following doses were used, simulating the human doses: 2.5 mg/kg for colistin, 7.5 mg/kg for doripenem, and 15 mg/kg for vancomycin. Treatment was given only once. Controls received either the inoculum only or the antimicrobial agent(s) only. The larvae were observed for survival every 24 h for 4 days.
RESULTS AND DISCUSSION
Lipid A profiles of the colistin-resistant strains. Lipid A modification with phosphoethanolamine in A. baumannii has been linked to colistin resistance (21, 22) . To determine if this modification was present on the terminal phosphates of lipid A isolated from the three clinical strains, MALDI-time of flight (TOF) mass spectrometry in the negative-ion mode was performed. Lipid A extracted after growth at 37°C in rich medium (lysogenic broth) showed three major [M-H] Ϫ ions at m/z 1,404, 1,910 (dominant), and 2,034 (Fig. 1) . The most abundant ion at m/z 1,910 corresponds to a bis-phosphorylated hepta-acylated lipid A. The ion at m/z 2,034 corresponds to the hepta-acylated lipid A (m/z 1,910) modified with a phosphoethanolamine at the 4= position (⌬m/z 125). This ion was absent in all three previous colistin-susceptible strains from the same patients. The ion at m/z 1,404 is a tetraacylated lipid A thought to be a breakdown product of lipid A isolation. These results indicate that resistance to colistin in these clinical strains is associated with the presence of the modified lipid A with phosphoethanolamine that reduces the electrostatic interaction of colistin to the negatively charged lipid A in the bacterial outer membrane.
Analysis of pmrCAB and lpxACD sequences. The pmrCAB loci of the colistin-resistant strains contained amino acid changes in either PmrA or PmrB. JA566 (colistin MIC, 4 g/ml) contained a change in the response regulator PmrA (Met12Ile) compared with the previous colistin-susceptible strain from the same patient. JA942 (colistin MIC, Ͼ256 g/ml) contained a change in PmrB (Gln277Lys), which belonged to the kinase domain of the histidine kinase. For JA637 (colistin MIC, Ͼ256 g/ml), the previous colistin-susceptible strain had insertions of IS3 in pmrC and ISAba21 in pmrB, making direct comparison not informative. Nonetheless, JA637 did contain a single-amino-acid change in PmrB (Gln270Pro), also in the kinase domain, compared with the published genome of colistin-susceptible A. baumannii strain MDR-ZJ06 belonging to Worldwide Clone 2 (23). None contained unique substitutions in PmrC. Likewise, none of the colistin-resistant strains contained amino acid changes in LpxA, LpxC, or LpxD compared with their colistin-susceptible counterparts.
Activities of colistin, doripenem, and vancomycin by susceptibility and synergy testing. The three clinical strains were resistant to colistin (MIC range, 4 to Ͼ256 g/ml), doripenem (MICs, Ͼ256 g/ml), and vancomycin (MICs, Ͼ256 g/ml) ( Table 1) . By the checkerboard method, synergy, defined as an FICI of Յ0.5, was consistently observed between COL and VAN across the three strains ( Table 1 ). The COL-DOR combination also showed synergy for two of the three strains, whereas the DOR-VAN combination was indifferent across the three strains.
Time-kill assays. None of the three agents displayed bactericidal activity when tested alone (Table 1 and Fig. 2 ). This included colistin tested against strain JA566, which had a relatively low MIC of 4 g/ml. When two agents were combined, the COL-DOR combination was consistently bactericidal, though regrowth was observed after 24 h in one strain. The COL-VAN combination gave mixed results, ranging from bacteriostatic activity to bactericidal activity without regrowth, depending on the strain. The DOR-VAN combination was still better than each agent alone but was not bactericidal for any of the strains. Of note, the combination of the three agents was bactericidal for all three strains, resulting in complete killing without regrowth (Fig. 1) . The activities of the COL-DOR and COL-VAN combinations observed here are in line with previous studies of colistin-susceptible strains where these combinations were bactericidal without regrowth for most but not all strains tested (10, 18) . The activity of vancomycin observed against A. baumannii clinical strains, especially in combination with colistin, is interesting as the activity of vancomycin is usually considered limited to Gram-positive organisms. It has been speculated that the membrane-permeabilizing effect of colistin may facilitate penetration of vancomycin toward the target peptidoglycan (10) . Our data show that this may be the case for colistin-resistant strains as well.
Activities of colistin, doripenem, and vancomycin in the G. mellonella infection model. The G. mellonella infection model for studies of A. baumannii pathogenesis and therapeutics was initially reported by Peleg et al. (20) and has subsequently been adopted by others (24) (25) (26) (27) (28) . Among them, Hornsey et al. (11) reported the efficacy of the COL-VAN combination in protecting G. mellonella from infection due to colistin-susceptible, carbap- enem-resistant A. baumannii strain AB210. We therefore applied this model to study the in vivo activities of the three agents against infection due to our three colistin-resistant strains. Importantly, administration of the antimicrobial agents alone or in combinations without infection did not affect the survival of the larvae compared with that of uninfected, untreated controls (data not shown). In this model, A. baumannii conferred approximately 90% lethality at 96 h in the absence of therapy ( Table 1) . As seen in Fig. 3 , most of the killing occurred in the first 24 h, followed by further killing in the subsequent 3 days, which was consistent with previous reports (9, 20) . Of the three monotherapies, only doripenem consistently provided significant survival advantage over controls (P Ͻ 0.05 by Student's t test). Of the four combination therapies, the DOR-VAN and COL-DOR-VAN combinations led to significantly improved survival for all three strains (P Ͻ 0.05). The best survival rates were observed with the former combination for strains JA566 and JA942 (68.3 and 81.7%, respectively) and with the latter combination for strain JA637 (80.0%). Overall, regimens containing doripenem yielded better survival than those which did not. Regimens containing colistin gave lower survival than otherwise equivalent regimens without colistin, especially for strain JA942 (Table 1, Fig. 3 ). Since colistin by itself was not found to negatively impact survival in the absence of infection, the reason for this phenomenon was not clear. G. mellonella is known to produce a repertoire of antimicrobial peptides in response to bacterial infection (29, 30) . One possibility is that colistin may interfere with the expression or function of these innate peptides. Alternatively, toxicity of colistin may be accentuated in the presence of acute infection. The G. mellonella model also differs from therapy of human infection in that colistin and not its prodrug, colistin methanesulfonate, is administered. Another interesting finding of these in vivo assays was the apparent effectiveness of doripenem and vancomycin monotherapy in im- proving survival despite the resistance of the strains to these agents and the lack of activity in the time-kill assays. A similar observation has been reported with vancomycin for a colistin-susceptible clinical strain (11) . The authors speculated that vancomycin may be able to prime the innate immune system in G. mellonella, resulting in protection which is not predicted by in vitro assays. A similar mechanism may also be at play for doripenem. For instance, exposure of neutrophils to carbapenems has been associated with increased phagocytic killing of pathogenic bacteria (31, 32) , and hemocytes of G. mellonella share similar kinetics of phagocytosis and microbial killing with human neutrophils (33) . Therefore, it is possible that certain immunologic effects are augmenting the antibacterial activity of these agents, leading to better efficacy than is observed in vitro. From a clinical perspective, additional studies are required to determine whether similar in vivo protection is achieved by these combinations in a vertebrate model.
Conclusion.
No viable therapy currently exists for infection due to XDR A. baumannii that has also become resistant to colistin. Our in vitro and in vivo findings reported here suggest that a combination therapy consisting of colistin, doripenem, and vancomycin-all of which these strains are resistant to-may be an effective therapeutic option for this condition and merits further investigation. These findings may be of clinical relevance, as vancomycin is often coadministered for concomitant Gram-positive infection or on an empirical basis to patients with colistin-resistant A. baumannii infection, who are severely ill and typically require intensive care.
